The American Society of Hematology (ASH) just opened draft recommendations for its clinical practice guideline, Dosing and Monitoring of Hydroxyurea for Sickle Cell Disease, to public comment. This guideline draft follows the 2024 decision that, due to long-standing member interest, a plan was put into place to develop clinical practice guidelines on dosing and monitoring of hydroxyurea for sickle cell disease.
All interested healthcare professionals, members of stakeholder organizations, and individuals are welcome to share feedback.
Click here for access to view the eleven draft recommendations.
The public comment window is open through January 20, 2026. To submit comments on the draft recommendations, email guidelines@hematology.org.
Sign up for alerts to keep up with the latest clinical guidelines and guideline updates.
Copyright © 2025 Guideline Central, all rights reserved.